Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: Results from phase III TRIBE trial by the gruppo oncologico del nord ovest

C. Cremolini, F. Loupakis, C. Antoniotti, S. Lonardi, G. Masi, L. Salvatore, E. Cortesi, G. Tomasello, R. Spadi, A. Zaniboni, G. Tonini, C. Barone, S. Vitello, R. Longarini, A. Bonetti, M. D'Amico, S. Di Donato, C. Granetto, L. Boni, Alfredo Falcone

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Background: Early tumor shrinkage (ETS) and depth of response (DoR) predict overall survival (OS) in first-line trials of chemotherapy ± anti-EGFR monoclonal antibodies in metastatic colorectal cancer (mCRC). These associations and the predictive accuracy of response measurements for survival parameters were investigated in the phase III TRIBE trial of FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev. Patients and methods: A landmark approach was adopted to define the assessable population. The distribution of RECIST response rate, ETS and DoR was compared in the two arms. Associations between response measurements and progression-free survival (PFS), post-progression survival (PPS) and OS were tested by univariate and multivariate Cox models. Prediction performance of each factor was estimated by C-index. Results: A significantly higher percentage of patients in the FOLFOXIRI plus bev arm achieved ETS ≥20%, when compared with the control arm (62.7% versus 51.9%, P = 0.025). Also the DoR was significantly higher in the triplet plus bev arm (43.4% versus 37.8%, P = 0.003). Both ETS and DoR were associated with PFS, PPS and OS at the univariate analyses and in the multivariate models stratified for other prognostic variables. Both ETS and DoR were able to predict survival as accurately as RECIST response. Conclusion: FOLFOXIRI plus bev improves ETS and DoR when compared with FOLFIRI plus bev. Achieving rapid and deep tumor shrinkage consistently delays tumor progression and prolongs survival in patients treated with first-line chemotherapy plus bev. ETS is a promising and valuable end point for clinical trials' design deserving further investigation.

Original languageEnglish
Pages (from-to)1188-1194
Number of pages7
JournalAnnals of Oncology
Volume26
Issue number6
DOIs
Publication statusPublished - Jun 1 2015

Fingerprint

Colorectal Neoplasms
Drug Therapy
Survival
Neoplasms
Disease-Free Survival
Bevacizumab
Proportional Hazards Models
Multivariate Analysis
Monoclonal Antibodies
Clinical Trials
Population

Keywords

  • Bevacizumab
  • Depth of response
  • Early tumor shrinkage
  • FOLFOXIRI

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab : Results from phase III TRIBE trial by the gruppo oncologico del nord ovest. / Cremolini, C.; Loupakis, F.; Antoniotti, C.; Lonardi, S.; Masi, G.; Salvatore, L.; Cortesi, E.; Tomasello, G.; Spadi, R.; Zaniboni, A.; Tonini, G.; Barone, C.; Vitello, S.; Longarini, R.; Bonetti, A.; D'Amico, M.; Di Donato, S.; Granetto, C.; Boni, L.; Falcone, Alfredo.

In: Annals of Oncology, Vol. 26, No. 6, 01.06.2015, p. 1188-1194.

Research output: Contribution to journalArticle

Cremolini, C, Loupakis, F, Antoniotti, C, Lonardi, S, Masi, G, Salvatore, L, Cortesi, E, Tomasello, G, Spadi, R, Zaniboni, A, Tonini, G, Barone, C, Vitello, S, Longarini, R, Bonetti, A, D'Amico, M, Di Donato, S, Granetto, C, Boni, L & Falcone, A 2015, 'Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: Results from phase III TRIBE trial by the gruppo oncologico del nord ovest', Annals of Oncology, vol. 26, no. 6, pp. 1188-1194. https://doi.org/10.1093/annonc/mdv112
Cremolini, C. ; Loupakis, F. ; Antoniotti, C. ; Lonardi, S. ; Masi, G. ; Salvatore, L. ; Cortesi, E. ; Tomasello, G. ; Spadi, R. ; Zaniboni, A. ; Tonini, G. ; Barone, C. ; Vitello, S. ; Longarini, R. ; Bonetti, A. ; D'Amico, M. ; Di Donato, S. ; Granetto, C. ; Boni, L. ; Falcone, Alfredo. / Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab : Results from phase III TRIBE trial by the gruppo oncologico del nord ovest. In: Annals of Oncology. 2015 ; Vol. 26, No. 6. pp. 1188-1194.
@article{377befc0129e401daf9693707a03a0f5,
title = "Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: Results from phase III TRIBE trial by the gruppo oncologico del nord ovest",
abstract = "Background: Early tumor shrinkage (ETS) and depth of response (DoR) predict overall survival (OS) in first-line trials of chemotherapy ± anti-EGFR monoclonal antibodies in metastatic colorectal cancer (mCRC). These associations and the predictive accuracy of response measurements for survival parameters were investigated in the phase III TRIBE trial of FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev. Patients and methods: A landmark approach was adopted to define the assessable population. The distribution of RECIST response rate, ETS and DoR was compared in the two arms. Associations between response measurements and progression-free survival (PFS), post-progression survival (PPS) and OS were tested by univariate and multivariate Cox models. Prediction performance of each factor was estimated by C-index. Results: A significantly higher percentage of patients in the FOLFOXIRI plus bev arm achieved ETS ≥20{\%}, when compared with the control arm (62.7{\%} versus 51.9{\%}, P = 0.025). Also the DoR was significantly higher in the triplet plus bev arm (43.4{\%} versus 37.8{\%}, P = 0.003). Both ETS and DoR were associated with PFS, PPS and OS at the univariate analyses and in the multivariate models stratified for other prognostic variables. Both ETS and DoR were able to predict survival as accurately as RECIST response. Conclusion: FOLFOXIRI plus bev improves ETS and DoR when compared with FOLFIRI plus bev. Achieving rapid and deep tumor shrinkage consistently delays tumor progression and prolongs survival in patients treated with first-line chemotherapy plus bev. ETS is a promising and valuable end point for clinical trials' design deserving further investigation.",
keywords = "Bevacizumab, Depth of response, Early tumor shrinkage, FOLFOXIRI",
author = "C. Cremolini and F. Loupakis and C. Antoniotti and S. Lonardi and G. Masi and L. Salvatore and E. Cortesi and G. Tomasello and R. Spadi and A. Zaniboni and G. Tonini and C. Barone and S. Vitello and R. Longarini and A. Bonetti and M. D'Amico and {Di Donato}, S. and C. Granetto and L. Boni and Alfredo Falcone",
year = "2015",
month = "6",
day = "1",
doi = "10.1093/annonc/mdv112",
language = "English",
volume = "26",
pages = "1188--1194",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "6",

}

TY - JOUR

T1 - Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab

T2 - Results from phase III TRIBE trial by the gruppo oncologico del nord ovest

AU - Cremolini, C.

AU - Loupakis, F.

AU - Antoniotti, C.

AU - Lonardi, S.

AU - Masi, G.

AU - Salvatore, L.

AU - Cortesi, E.

AU - Tomasello, G.

AU - Spadi, R.

AU - Zaniboni, A.

AU - Tonini, G.

AU - Barone, C.

AU - Vitello, S.

AU - Longarini, R.

AU - Bonetti, A.

AU - D'Amico, M.

AU - Di Donato, S.

AU - Granetto, C.

AU - Boni, L.

AU - Falcone, Alfredo

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Background: Early tumor shrinkage (ETS) and depth of response (DoR) predict overall survival (OS) in first-line trials of chemotherapy ± anti-EGFR monoclonal antibodies in metastatic colorectal cancer (mCRC). These associations and the predictive accuracy of response measurements for survival parameters were investigated in the phase III TRIBE trial of FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev. Patients and methods: A landmark approach was adopted to define the assessable population. The distribution of RECIST response rate, ETS and DoR was compared in the two arms. Associations between response measurements and progression-free survival (PFS), post-progression survival (PPS) and OS were tested by univariate and multivariate Cox models. Prediction performance of each factor was estimated by C-index. Results: A significantly higher percentage of patients in the FOLFOXIRI plus bev arm achieved ETS ≥20%, when compared with the control arm (62.7% versus 51.9%, P = 0.025). Also the DoR was significantly higher in the triplet plus bev arm (43.4% versus 37.8%, P = 0.003). Both ETS and DoR were associated with PFS, PPS and OS at the univariate analyses and in the multivariate models stratified for other prognostic variables. Both ETS and DoR were able to predict survival as accurately as RECIST response. Conclusion: FOLFOXIRI plus bev improves ETS and DoR when compared with FOLFIRI plus bev. Achieving rapid and deep tumor shrinkage consistently delays tumor progression and prolongs survival in patients treated with first-line chemotherapy plus bev. ETS is a promising and valuable end point for clinical trials' design deserving further investigation.

AB - Background: Early tumor shrinkage (ETS) and depth of response (DoR) predict overall survival (OS) in first-line trials of chemotherapy ± anti-EGFR monoclonal antibodies in metastatic colorectal cancer (mCRC). These associations and the predictive accuracy of response measurements for survival parameters were investigated in the phase III TRIBE trial of FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev. Patients and methods: A landmark approach was adopted to define the assessable population. The distribution of RECIST response rate, ETS and DoR was compared in the two arms. Associations between response measurements and progression-free survival (PFS), post-progression survival (PPS) and OS were tested by univariate and multivariate Cox models. Prediction performance of each factor was estimated by C-index. Results: A significantly higher percentage of patients in the FOLFOXIRI plus bev arm achieved ETS ≥20%, when compared with the control arm (62.7% versus 51.9%, P = 0.025). Also the DoR was significantly higher in the triplet plus bev arm (43.4% versus 37.8%, P = 0.003). Both ETS and DoR were associated with PFS, PPS and OS at the univariate analyses and in the multivariate models stratified for other prognostic variables. Both ETS and DoR were able to predict survival as accurately as RECIST response. Conclusion: FOLFOXIRI plus bev improves ETS and DoR when compared with FOLFIRI plus bev. Achieving rapid and deep tumor shrinkage consistently delays tumor progression and prolongs survival in patients treated with first-line chemotherapy plus bev. ETS is a promising and valuable end point for clinical trials' design deserving further investigation.

KW - Bevacizumab

KW - Depth of response

KW - Early tumor shrinkage

KW - FOLFOXIRI

UR - http://www.scopus.com/inward/record.url?scp=84938086499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938086499&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdv112

DO - 10.1093/annonc/mdv112

M3 - Article

C2 - 25712456

AN - SCOPUS:84938086499

VL - 26

SP - 1188

EP - 1194

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 6

ER -